IMPORTANT NOTICE ABOUT COMMENTS

Because of spam, I personally moderate all comments left on my blog. That means you will not see your comment when you post it. It will instead show up within 48 hours, along with my response if one is appropriate.

All comments are welcome and will be posted, even if they are negative. You just can't promote other sites or products in them.

If you have a personal question about LI or any related topic you can send me an email at stevecarper@cs.com.

Otherwise, this blog and my Lactose Intolerance Clearinghouse are now legacy sites, meaning that I am not updating them any longer. The basic information about LI is still sound. However, product information and weblinks may be out of date.

My old website can be found at www.stevecarper.com/li

For quick offline reference, you can purchase Planet Lactose: The Best of the Blog as an ebook on Smashwords.com or Amazon.com or BarnesandNoble.com or a whole lot of other places that Smashwords is suppose to distribute the book to. Almost 100,000 words on LI, allergies, milk products, milk-free products, and the genetics of intolerance, along with large helpings of the weirdness that is the Net.

Thursday, September 10, 2009

Lactagen Prepares to File For New Drug

Ritter Pharmaceuticals, Inc., the makers of Lactagen, are gearing up for the release of a new drug for lactose intolerance. They've hired a new Chief Medical Officer in preparation for an IND, investigational new drug, filing with the FDA.

The company issued a press release on this.

Ritter Pharmaceuticals, Inc. (Ritter) has hired Howard Foyt, M.D., Ph.D., FACP as its new Executive VP, Development & Chief Medical Officer. Dr. Foyt brings 13 years of expertise in drug development to Ritter, as the Company prepares to file an IND for its therapy for Lactose Intolerance.

Dr. Foyt will join Ritter's senior management team and oversee the Company's clinical development efforts. Ritter will take advantage of Dr. Foyt's leadership in drug development within big pharma and biotech companies. For the past three years, Dr. Foyt served as VP, Clinical Development and Chief Medical Officer at Metabasis Therapeutics, where he was responsible for five drugs in clinical development over multiple therapeutic areas. Dr. Foyt had previously worked at Pfizer, where he served as Senior Director and Site Head - Diabetes & Obesity, and earlier at Parke-Davis for over ten years participating in the clinical development of multiple drugs mainly in the metabolic disease field. Prior to joining Parke-Davis, Dr. Foyt was on the faculty at the University of Texas Medical Branch, Galveston, TX. He earned
his medical degree and Ph.D. in Cell Biology from Baylor College of Medicine. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. ...

Ritter's first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.

Bookmark and Share

No comments: